Background: The purpose of this study was to evaluate potential predictors of no-shows and late cancellations in an outpatient clinic within a large healthcare system serving vulnerable communities.
Methods: Demographic data and appointment status were recorded for 537 consecutive patients scheduled for neuropsychological evaluation in an outpatient psychiatry clinic. Patients include 220 males and 317 females with an average formal education of 11.
The development of scientific predictive models has been of great interest over the decades. A scientific model is capable of forecasting domain outcomes without the necessity of performing expensive experiments. In particular, in combustion kinetics, the model can help improving the combustion facilities and the fuel efficiency reducing the pollutants.
View Article and Find Full Text PDFFast-pyrolysis bio-oils (FPBOs) obtained from lignocellulosic biomass are gaining attention as sustainable fuels for various applications, including the transport sector and power production. A significant fraction of bio-oils is constituted by nitrogen-containing compounds (N fuels) that should be considered when developing surrogate models for FPBOs. Moreover, the content of N fuels in FPBOs is expected to strongly contribute to the production of nitrogen oxides (NO ) directly from fuel-bound nitrogen (fuel NO ), in addition to the thermal NO formation pathways typical of high-temperature combustion conditions.
View Article and Find Full Text PDFFast biomass pyrolysis is an effective and promising process for high bio-oil yields, and represents one of the front-end technologies to provide alternative, sustainable fuels as a replacement of conventional, fossil-based ones. In this work, the effect of droplet initial diameter on the evaporation and ignition of droplets of crude fast pyrolysis bio-oil (FPBO) and FPBO/ethanol blend (50% vol) at ambient pressure is discussed. The experimental tests were carried out in a closed single droplet combustion chamber equipped with optical accesses, using droplets with a diameter in the range of 0.
View Article and Find Full Text PDFIntroduction: Sorafenib, an oral multikinase inhibitor, is the only systemic agent proven to be effective in patients with hepatocellular carcinoma (HCC). There are no approved second line systemic therapies in patients who have had disease progression on or are not eligible to sorafenib.
Case Presentation: We describe two cases of unresectable HCC that were treated with low, "metronomic" doses of capecitabine.